Status:
RECRUITING
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Metabolic reprogramming has been identified as a hallmark of cancer. Almost a century after Otto Warburg initially discovered increased glycolytic activity in tumor tissue ("Warburg effect"), therapeu...
Eligibility Criteria
Inclusion
- Group A
- Adult (18 years of age or older)
- No previous history of cancer
- Routine history of normal blood counts and vital signs
- Documented Informed Consent
- Group B
- Adult (18 years of age or older)
- Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.)
- Treatment naïve
- Documented Informed Consent
- Group C
- Adult (18 years of age or older)
- Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia
- Treatment naïve
- Able/willing to have bone marrow aspiration
- Documented Informed Consent
Exclusion
- For all participants
- Prisoners
- Psychiatric inpatients or people who are institutionalized
- Minor (Less than 18 years of age)
- History of diabetes
- Cannot be on antihyperglycemic therapy
- Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc.
- Females of child bearing potential
- Persons without decision-making capacity
- Person who cannot read/write English
- Not meeting inclusion criteria defined above
Key Trial Info
Start Date :
June 13 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04785989
Start Date
June 13 2022
End Date
October 1 2026
Last Update
November 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53705